Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer

Summary

This phase II trial studies how well copanlisib works in treating patients with endometrial cancer that has not decreased or disappeared, and the cancer may still be in the body despite treatment (persistent) or has come back (recurrent). Copanlisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Timeline

Start

2016-09-16

Primary completion

2018-08-18

Completion

2020-02-14

Drugs

Indications